Response to Soliris May Take Longer Than 3 Months for Some With gMG

Response to Soliris May Take Longer Than 3 Months for Some With gMG

296131

Response to Soliris May Take Longer Than 3 Months for Some With gMG

Most generalized myasthenia gravis (gMG) patients respond to Soliris (eculizumab) within three months of treatment, but some have to wait longer to achieve clinical responses, according to a post-hoc analysis of data from the Phase 3 REGAIN trial and its extension study. Notably, patients’ characteristics as evaluated at treatment start did not identify predictors of early versus late responses. While the analysis was unable to determine Soliris’ minimum treatment time before a well-informed decision on whether to…

You must be logged in to read/download the full post.